glp-1 and crohn's disease Patients with inflammatory bowel who received a RA had a 5-year CRC incidence of 0.2% compared with 0.42% in non-GLP-1 RA users (OR, 0.49)., https://hubs.li/Q04myj2G0, #crcsm #IBD GI and Hepatology News -

Benefits of Glutathione IV Therapy Glutathione IV therapy hits hard against the effects of low antioxidant levels by delivering it straight to your bloodstream, skipping the guts roadblocks

The FDA also notes that 28 days is the assumed opened-vial period for this kind of container unless the label specifies something else

Although AI shows promise, issues such as limited data diversity and low model interpretability hinder its generalizability and clinical trust

In contrast, MK-7, while also neuroprotective, appears to have a longer half-life and greater bioavailability, potentially leading to sustained effects over time